Free tool
FAERS Monitor: Unloxcyt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761297 or its brand name (Unloxcyt, Cosibelimab-Ipdl). Reports on generic versions are filed under their own applications.
Reports
7
Serious
1
14% of reports
Hospitalization
0
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- alopecia1
- death1
- fatigue1
- illness1
- liver disorder1
- product storage error1
- product storage issue1
- pruritus1
- swelling face1
- therapy cessation1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,152 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product storage issue | 1 | 793.4 | 129.2 | 197 |
| liver disorder | 1 | 67.8 | 11.0 | 16 |
| therapy cessation | 1 | 58.5 | 9.5 | 14 |
| swelling face | 1 | 46.1 | 7.5 | 11 |
| product storage error | 1 | 34.3 | 5.6 | 8 |
| illness | 1 | 29.2 | 4.8 | 6 |
| alopecia | 1 | 15.3 | 2.5 | 3 |
| pruritus | 1 | 7.8 | 1.3 | 1 |
| fatigue | 1 | 3.9 | 0.6 | 0 |
| death | 1 | 3.5 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.